Antibodies to il-6 and use thereof

Patent metadata

Field	Value
Publication number	US-2020040074-A1
Application number	US-201916356468-A
Country	US
Kind code	A1
Filing date	Mar 18, 2019
Priority date	May 21, 2007
Publication date	Feb 6, 2020
Grant date	—

Abstract

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

First claim

1 . An anti-human IL-6 antibody or antibody fragment which specifically binds to the same linear or conformational epitope(s) and/or competes for binding to the same linear or conformational epitope(s) on an intact human IL-6 polypeptide or fragment thereof as an anti-human IL-6 antibody selected from the group consisting of Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, Ab10, Ab11, Ab12, Ab13, Ab14, Ab15, Ab16, Ab17, Ab18, Ab19, Ab20, Ab21, Ab22, Ab23, Ab24, Ab25, Ab26, Ab27, Ab28, Ab29, Ab30, Ab31, Ab32, Ab33, Ab34, Ab35, and Ab36 or an anti-IL-6 antibody containing the variable light region contained in any one of the SEQ ID NO:647-651 and a variable heavy chain region contained in any one of SEQ ID NO:s 652-658.

2 - 137 . (canceled)

Assignees

• Alderbio Holdings Llc

Inventors

• Garcia-Martinez Leon F
• Carvalho Jensen Anne Elisabeth
• Anderson Katie
• Dutzar Benjamin H
• Ojala Ethan W
• Kovacevich Brian R
• Latham John A
• Smith Jeffrey T L

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C12N15/81

  for yeasts · CPC title

• C12P21/02

  having a known sequence of two or more amino acids, e.g. glutathione · CPC title

• C07K2317/41

  Glycosylation, sialylation, or fucosylation · CPC title

• A61K2039/505

  comprising antibodies · CPC title